SECsense Logo

BioCryst Pharmaceuticals 8-K Report: Key Updates for Investors

$BCRX
Form 8-K
Filed on: 2025-02-24
Source
BioCryst Pharmaceuticals 8-K Report: Key Updates for Investors

Based on the provided financial report section, here are the key pieces of information extracted:

  1. Filing Information:
  • Filing Type: Form 8-K
  • Filing Date: February 24, 2025
  1. Company Information:
  • Company Name: BioCryst Pharmaceuticals, Inc.
  • State of Incorporation: Delaware (DE)
  • CIK Number: 0000882796
  • Company Identifier: 000-23186
  • EIN: 62-1413174
  • Address: 4505 Emperor Blvd., Suite 200, Durham, NC 27703
  • Phone Number: 919-859-1302
  1. Stock Information:
  • Common Stock Ticker: BCRX
  • Exchange: NASDAQ
  1. Units of Measure:
  • Currency: USD (U.S. Dollars)
  • Shares: The document indicates a measure of shares, though specific quantities are not provided in this excerpt.
  1. Context Information:
  • Context ID: Form8K
  • Reporting Period: The reporting period begins and ends on February 24, 2025.

Insights:

  • The report pertains to an 8-K filing, which typically indicates that the company is reporting a significant event that shareholders should know about, such as mergers, acquisitions, or financial changes.
  • The company is publicly listed on NASDAQ under the ticker BCRX, indicating its engagement with investors and the broader market.
  • The information suggests that the company is located in Durham, NC, which may be relevant for regional economic or market analyses.

This information is crucial for stakeholders looking to assess the company's recent developments or their implications on stock performance.